As on Tuesday, Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) got off with the flyer as it spiked 0.95% to $22.42, before settling in for the price of $22.21 at the close. Taking a more long-term approach, TEVA posted a 52-week range of $10.34-$22.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -2.68% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 26.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -3.17%. This publicly-traded company’s shares outstanding now amounts to $1.13 billion, simultaneously with a float of $1.13 billion. The organization now has a market capitalization sitting at $25.45 billion. At the time of writing, stock’s 50-day Moving Average stood at $18.00, while the 200-day Moving Average is $16.72.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Teva- Pharmaceutical Industries Ltd. ADR’s current insider ownership accounts for 0.01%, in contrast to 56.89% institutional ownership. Preceding that transaction, on Nov 20 ’24, Company’s EVP, Head of U.S. Commercial sold 19,388 for 16.87, making the whole transaction’s value amount to 327,085. This particular insider is now the holder of 44,104 in total.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Earnings and Revenue Records
Teva- Pharmaceutical Industries Ltd. ADR’s EPS decrease for this current 12-month fiscal period is -3.17% and is forecasted to reach 2.81 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.25% through the next 5 years, which can be compared against the 26.63% growth it accomplished over the previous five years trading on the market.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators
Let’s observe the current performance indicators for Teva- Pharmaceutical Industries Ltd. ADR (TEVA). It’s Quick Ratio in the last reported quarter now stands at 0.61. The Stock has managed to achieve an average true range (ATR) of 0.83. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.51. Similarly, its price to free cash flow for trailing twelve months is now 9.29.
In the same vein, TEVA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.85, a figure that is expected to reach 0.70 in the next quarter, and analysts are predicting that it will be 2.81 at the market close of one year from today.
Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Through scrutinizing the latest numbers posted by the [Teva- Pharmaceutical Industries Ltd. ADR, TEVA], it can be observed that its last 5-days Average volume of 13.24 million was better the volume of 9.43 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 98.87% While, its Average True Range was 0.92.
Raw Stochastic average of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) in the period of the previous 100 days is set at 98.80%, which indicates a major rise in contrast to 98.72% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 99.86% that was higher than 47.06% volatility it exhibited in the past 100-days period.
